The direct oral anticoagulants (doacs) device market size has grown strongly in recent years. It will grow from $32.8 billion in 2025 to $35.69 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited availability of doac monitoring devices, reliance on hospital-based coagulation tests, growing prevalence of atrial fibrillation and thrombotic disorders, adoption of oral anticoagulant therapies, increasing demand for patient safety and anticoagulation monitoring.
The direct oral anticoagulants (doacs) device market size is expected to see strong growth in the next few years. It will grow to $49.48 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to technological advancements in portable and point-of-care devices, integration with digital health platforms and cloud-based monitoring, rising adoption of personalized anticoagulation management, expansion of homecare and specialty clinic services, increasing regulatory approvals for novel monitoring systems. Major trends in the forecast period include growing adoption of point-of-care doac monitoring devices, increasing use of factor xa and direct thrombin inhibitor monitoring, rising awareness of stroke and thromboembolism prevention, expansion of homecare and ambulatory monitoring solutions, enhanced focus on accuracy, sensitivity, and rapid testing capabilities.
The rising prevalence of cardiovascular disorders is expected to drive the growth of the direct oral anticoagulants (DOACs) device market in the coming years. Cardiovascular disorders encompass a broad range of conditions affecting the heart and blood vessels, frequently resulting in complications such as heart attacks, strokes, and other circulatory system disorders. The incidence of cardiovascular disorders is increasing due to progressively sedentary lifestyles, which contribute to weight gain, elevated blood pressure, and gradual deterioration of cardiovascular health. Direct oral anticoagulants (DOACs) support the management of cardiovascular disorders by effectively reducing the risk of stroke and blood clot formation in patients with atrial fibrillation, while providing consistent anticoagulation without requiring routine blood monitoring. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease resulted in 919,032 deaths in 2023, representing approximately one in every three deaths. Coronary heart disease remained the most common form of heart disease, and notably, around one in six cardiovascular-related deaths occurred among adults under the age of 65. Therefore, the increasing prevalence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.
Companies in the direct oral anticoagulants (DOACs) device market are developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of anticoagulant monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines to measure blood clotting speed, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched three coagulation tests designed specifically for Factor Xa inhibitors. These tests allow clinicians to accurately assess the anticoagulation status of patients taking rivaroxaban, apixaban, edoxaban, and heparin, supporting critical decisions during bleeding events, overdoses, or urgent surgeries. Using Roche’s reagent cassette technology on cobas t analyzers, these automated assays deliver reliable results, reduce manual handling, and optimize laboratory workflow efficiency.
In July 2024, Perosphere Technologies Inc., a US-based medical diagnostics company, partnered with CoRRect Medical to exclusively distribute its reagent-free point-of-care coagulometer in Germany. This partnership aims to meet unmet needs in coagulation testing by enabling rapid bedside assessment of anticoagulation status, particularly for patients on direct oral anticoagulants, improving treatment decisions, patient outcomes, and reducing healthcare costs. CoRRect Medical is a Germany-based medical device company.
Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the direct oral anticoagulants (doacs) device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the direct oral anticoagulants device market by increasing the cost of imported monitoring instruments and diagnostic components, particularly affecting segments such as factor xa and direct thrombin inhibitor monitoring devices. Regions in Asia-Pacific including China and India face higher import duties, which impact production and distribution costs. Despite these challenges, tariffs have encouraged local manufacturing initiatives, investment in domestic production capabilities, and innovation in cost-effective DOAC monitoring solutions.
The direct oral anticoagulants (doacs) device market research report is one of a series of new reports that provides direct oral anticoagulants (doacs) device market statistics, including direct oral anticoagulants (doacs) device industry global market size, regional shares, competitors with a direct oral anticoagulants (doacs) device market share, detailed direct oral anticoagulants (doacs) device market segments, market trends and opportunities, and any further data you may need to thrive in the direct oral anticoagulants (doacs) device industry. This direct oral anticoagulants (doacs) device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Direct oral anticoagulant (DOAC) devices are medical instruments or diagnostic tools designed to monitor and manage the blood-thinning effects of direct oral anticoagulant medications. These devices enable clinicians to assess anticoagulation status and drug levels in patients taking medications such as rivaroxaban, apixaban, edoxaban, or dabigatran, ensuring safe and effective therapy.
The primary products of DOAC devices include factor Xa inhibitors and direct thrombin inhibitors. Factor Xa inhibitors are anticoagulant medications that selectively block the activity of factor Xa, a key enzyme in the blood coagulation cascade, preventing the formation of harmful blood clots. They are commonly used to manage conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, heart attacks, and post-surgical thromboprophylaxis. Their applications cover stroke prevention, venous thromboembolism prevention, treatment of acute thrombotic events, long-term prophylaxis, and more. These devices are utilized by hospitals, ambulatory surgical centers, specialty clinics, homecare settings, and other healthcare providers.
The direct oral anticoagulants (DOACs) device market consists of sales of drug delivery devices, monitoring devices, adherence management tools and digital health platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The direct oral anticoagulants (doacs) device market size is expected to see strong growth in the next few years. It will grow to $49.48 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to technological advancements in portable and point-of-care devices, integration with digital health platforms and cloud-based monitoring, rising adoption of personalized anticoagulation management, expansion of homecare and specialty clinic services, increasing regulatory approvals for novel monitoring systems. Major trends in the forecast period include growing adoption of point-of-care doac monitoring devices, increasing use of factor xa and direct thrombin inhibitor monitoring, rising awareness of stroke and thromboembolism prevention, expansion of homecare and ambulatory monitoring solutions, enhanced focus on accuracy, sensitivity, and rapid testing capabilities.
The rising prevalence of cardiovascular disorders is expected to drive the growth of the direct oral anticoagulants (DOACs) device market in the coming years. Cardiovascular disorders encompass a broad range of conditions affecting the heart and blood vessels, frequently resulting in complications such as heart attacks, strokes, and other circulatory system disorders. The incidence of cardiovascular disorders is increasing due to progressively sedentary lifestyles, which contribute to weight gain, elevated blood pressure, and gradual deterioration of cardiovascular health. Direct oral anticoagulants (DOACs) support the management of cardiovascular disorders by effectively reducing the risk of stroke and blood clot formation in patients with atrial fibrillation, while providing consistent anticoagulation without requiring routine blood monitoring. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease resulted in 919,032 deaths in 2023, representing approximately one in every three deaths. Coronary heart disease remained the most common form of heart disease, and notably, around one in six cardiovascular-related deaths occurred among adults under the age of 65. Therefore, the increasing prevalence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.
Companies in the direct oral anticoagulants (DOACs) device market are developing advanced solutions, such as automated coagulation assays, to enhance the accuracy, efficiency, and consistency of anticoagulant monitoring in clinical laboratories. Automated coagulation assays are laboratory tests performed by machines to measure blood clotting speed, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched three coagulation tests designed specifically for Factor Xa inhibitors. These tests allow clinicians to accurately assess the anticoagulation status of patients taking rivaroxaban, apixaban, edoxaban, and heparin, supporting critical decisions during bleeding events, overdoses, or urgent surgeries. Using Roche’s reagent cassette technology on cobas t analyzers, these automated assays deliver reliable results, reduce manual handling, and optimize laboratory workflow efficiency.
In July 2024, Perosphere Technologies Inc., a US-based medical diagnostics company, partnered with CoRRect Medical to exclusively distribute its reagent-free point-of-care coagulometer in Germany. This partnership aims to meet unmet needs in coagulation testing by enabling rapid bedside assessment of anticoagulation status, particularly for patients on direct oral anticoagulants, improving treatment decisions, patient outcomes, and reducing healthcare costs. CoRRect Medical is a Germany-based medical device company.
Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the direct oral anticoagulants (doacs) device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the direct oral anticoagulants device market by increasing the cost of imported monitoring instruments and diagnostic components, particularly affecting segments such as factor xa and direct thrombin inhibitor monitoring devices. Regions in Asia-Pacific including China and India face higher import duties, which impact production and distribution costs. Despite these challenges, tariffs have encouraged local manufacturing initiatives, investment in domestic production capabilities, and innovation in cost-effective DOAC monitoring solutions.
The direct oral anticoagulants (doacs) device market research report is one of a series of new reports that provides direct oral anticoagulants (doacs) device market statistics, including direct oral anticoagulants (doacs) device industry global market size, regional shares, competitors with a direct oral anticoagulants (doacs) device market share, detailed direct oral anticoagulants (doacs) device market segments, market trends and opportunities, and any further data you may need to thrive in the direct oral anticoagulants (doacs) device industry. This direct oral anticoagulants (doacs) device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Direct oral anticoagulant (DOAC) devices are medical instruments or diagnostic tools designed to monitor and manage the blood-thinning effects of direct oral anticoagulant medications. These devices enable clinicians to assess anticoagulation status and drug levels in patients taking medications such as rivaroxaban, apixaban, edoxaban, or dabigatran, ensuring safe and effective therapy.
The primary products of DOAC devices include factor Xa inhibitors and direct thrombin inhibitors. Factor Xa inhibitors are anticoagulant medications that selectively block the activity of factor Xa, a key enzyme in the blood coagulation cascade, preventing the formation of harmful blood clots. They are commonly used to manage conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, heart attacks, and post-surgical thromboprophylaxis. Their applications cover stroke prevention, venous thromboembolism prevention, treatment of acute thrombotic events, long-term prophylaxis, and more. These devices are utilized by hospitals, ambulatory surgical centers, specialty clinics, homecare settings, and other healthcare providers.
The direct oral anticoagulants (DOACs) device market consists of sales of drug delivery devices, monitoring devices, adherence management tools and digital health platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Direct Oral Anticoagulants (DOACs) Device Market Characteristics
3. Direct Oral Anticoagulants (DOACs) Device Market Supply Chain Analysis
4. Global Direct Oral Anticoagulants (DOACs) Device Market Trends and Strategies
5. Direct Oral Anticoagulants (DOACs) Device Market Analysis of End Use Industries
7. Global Direct Oral Anticoagulants (DOACs) Device Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Direct Oral Anticoagulants (DOACs) Device Total Addressable Market (TAM) Analysis for the Market
9. Direct Oral Anticoagulants (DOACs) Device Market Segmentation
10. Direct Oral Anticoagulants (DOACs) Device Market Regional and Country Analysis
11. Asia-Pacific Direct Oral Anticoagulants (DOACs) Device Market
12. China Direct Oral Anticoagulants (DOACs) Device Market
13. India Direct Oral Anticoagulants (DOACs) Device Market
14. Japan Direct Oral Anticoagulants (DOACs) Device Market
15. Australia Direct Oral Anticoagulants (DOACs) Device Market
16. Indonesia Direct Oral Anticoagulants (DOACs) Device Market
17. South Korea Direct Oral Anticoagulants (DOACs) Device Market
18. Taiwan Direct Oral Anticoagulants (DOACs) Device Market
19. South East Asia Direct Oral Anticoagulants (DOACs) Device Market
20. Western Europe Direct Oral Anticoagulants (DOACs) Device Market
21. UK Direct Oral Anticoagulants (DOACs) Device Market
22. Germany Direct Oral Anticoagulants (DOACs) Device Market
23. France Direct Oral Anticoagulants (DOACs) Device Market
24. Italy Direct Oral Anticoagulants (DOACs) Device Market
25. Spain Direct Oral Anticoagulants (DOACs) Device Market
26. Eastern Europe Direct Oral Anticoagulants (DOACs) Device Market
27. Russia Direct Oral Anticoagulants (DOACs) Device Market
28. North America Direct Oral Anticoagulants (DOACs) Device Market
29. USA Direct Oral Anticoagulants (DOACs) Device Market
30. Canada Direct Oral Anticoagulants (DOACs) Device Market
31. South America Direct Oral Anticoagulants (DOACs) Device Market
32. Brazil Direct Oral Anticoagulants (DOACs) Device Market
33. Middle East Direct Oral Anticoagulants (DOACs) Device Market
34. Africa Direct Oral Anticoagulants (DOACs) Device Market
36. Direct Oral Anticoagulants (DOACs) Device Market Competitive Landscape and Company Profiles
37. Direct Oral Anticoagulants (DOACs) Device Market Other Major and Innovative Companies
40. Direct Oral Anticoagulants (DOACs) Device Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Direct Oral Anticoagulants (DOACs) Device Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses direct oral anticoagulants (doacs) device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for direct oral anticoagulants (doacs) device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The direct oral anticoagulants (doacs) device market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Factor Xa Inhibitors; Direct Thrombin Inhibitors2) By Disease: Atrial Fibrillation; Deep Vein Thrombosis; Pulmonary Embolism; Heart Attacks; Post-Surgical Thromboprophylaxis; Other Diseases
3) By Application: Stroke Prevention; Venous Thromboembolism Prevention; Treatment Of Acute Thrombotic Events; Long-Term Prophylaxis; Other Applications
4) By End User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Homecare Settings; Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices; Apixaban Monitoring Devices; Edoxaban Monitoring Devices; Betrixaban Monitoring Devices2) By Direct Thrombin Inhibitors: Dabigatran Etexilate; Dabigatran Mesylate
Companies Mentioned: Pfizer Inc.; Roche Diagnostics Corporation; Bristol-Myers Squibb Company; Siemens Healthcare GmbH; Becton Dickinson And Company; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Limited; Daiichi Sankyo Co. Ltd; Sysmex Corporation; Dr. Reddy’s Laboratories Limited; Werfen S.A.; Alembic Pharmaceuticals Limited; Diagnostica Stago SAS; Helena Laboratories Corporation; iLine Microsystems S.L.; Technoclone GmbH; Anthos Therapeutics Inc.; FLoBio LLC; Perosphere Technologies Inc.; DOASENSE GmbH.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Direct Oral Anticoagulants (DOACs) Device market report include:- Pfizer Inc.
- Roche Diagnostics Corporation
- Bristol-Myers Squibb Company
- Siemens Healthcare GmbH
- Becton Dickinson And Company
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Limited
- Daiichi Sankyo Co. Ltd
- Sysmex Corporation
- Dr. Reddy’s Laboratories Limited
- Werfen S.A.
- Alembic Pharmaceuticals Limited
- Diagnostica Stago SAS
- Helena Laboratories Corporation
- iLine Microsystems S.L.
- Technoclone GmbH
- Anthos Therapeutics Inc.
- FLoBio LLC
- Perosphere Technologies Inc.
- DOASENSE GmbH.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 35.69 Billion |
| Forecasted Market Value ( USD | $ 49.48 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
